PURIFICATION

CROSS REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority to U.S. provisional patent application no.

62/240,863, filed October 13, 2015, the disclosure of which is incorporated herein by reference.

FIELD

[0002] The present disclosure relates generally to compositions and methods for improving recombinant protein production. The recombinant proteins use Ribose Binding Protein for enhancing protein expression.

BACKGROUND

[0003] Many naturally occurring proteins and peptides are of great interest in research, medical, and industrial applications, but obtaining them in sufficient quantities from their natural hosts can be problematic because of low purity or natural abundance. Furthermore, engineering the proteins for altered or improved properties is all but impossible in most native hosts (e.g. insulin from pigs or cows). As a result, scientists have turned to recombinant protein expression in model organisms whose genetics can be manipulated to cause overexpression of proteins not natively found in the host.

[0004] For technical reasons, microorganisms like E. coli and S. cerevisiae are the preferred hosts for recombinant protein expression. However, because model microorganisms lack the protein folding machinery and regulatory mechanisms of the organisms from which most proteins of interest originate (e.g. mammals), proteins are often translated poorly or fold improperly from expression constructs (recombinant DNA molecules encoding the protein being produced and other elements necessary for expression), resulting in poor protein expression, solubility and ultimately low yield. There is thus an ongoing and unmet need for improved compositions and methods for improving recombinant protein production.

SUMMARY

[0005] The present disclosure encompasses compositions and methods for increasing protein production. In general the compositions and methods include expression vectors, recombinant fusion proteins encoded by them, cells comprising the expression vectors, and isolated/purified recombinant fusion proteins, and fragments thereof. The fusion proteins comprise a polypeptide of interest (also referred to herein as a "target protein") and a segment that comprises a Ribose Binding Protein (RBP), or at least a contiguous portion of an RBP, such that production of the fusion protein is increased. The fusion proteins can be configured to include a segment that is useful for liberating the target protein from the RBP and other non- target protein portions of the fusion protein. [0006] Increases in protein production made possible by the present disclosure can be determined by comparison to any suitable reference, including but not necessarily limited to a value that represents the actual or expected or predicted or calculated expression of the target protein when an RBP segment is not present in the same polypeptide that includes the target protein. [0007] The disclosure is illustrated by non-limiting embodiments that demonstrate RBP- fusion protein production comprising functionally and structurally distinct proteins having different sizes and amino acid profiles. In particular and representative demonstrations, recombinant fusion protein production is illustrated in a prokaryotic system using a modified RBP derived from the RBP produced by Thermoanaerobacter tengcongensis (T. tengcongensis), but it will be apparent that other RBPs can be substituted. In particular embodiments, the disclosure demonstrates recombinant protein production using RBPs expressed in a single polypeptide with human p53, WD-Repeat Protein 5 (WDR5) from Drosophila melanogaster, actin from Saccharomyces cerevisiae, human rhinovirus 3C (HRV 3C) protease, and Mouse double minute 2 homolog (MDM2) also known as E3 ubiquitin-protein ligase Mdm2. The MDM2 has the amino acid sequence of the mouse and human proteins, as they are identical. Thus, the disclosure demonstrates broad applicability to express, and increase expression, of a variety of distinct proteins, and it is expected there are no particular limitations to the type of proteins that can be used in one or more embodiments of the invention.

[0008] A representative RBP sequence is provided in SEQ ID NO:2. This sequence comprises a Cysl02Ser alternation relative to the wild type T. tengcongensis sequence. Further, it has been determined that enhanced expression of a target protein as a component of a fusion protein described herein does not require the entire length of the RBP. In this regard, in certain embodiments, the disclosure comprises expression vectors, the proteins encoded by them, and other embodiments, wherein the entire RBP segment is not essential. Additionally, the disclosure differs from other systems that have used RBPs in fusion proteins, such as in domain swapping configurations, because the RBP or a segment thereof is provided sequentially with the target protein. As such, in various implementations, the RBP of this disclosure does not interrupt the target protein. In certain approaches, the disclosure includes expression vectors and the fusion proteins encoded by them, wherein the fusion proteins comprise truncations at the N- terminus of the RBP component of from 1-33 amino acids, inclusive and including all integers and all ranges of integers there between, and/or at the C-terminus of the RBP component of from 1-67 amino acids, inclusive and including all integers and all ranges of integers there between. Accordingly, in one approach the disclosure provides a recombinant expression vector encoding a fusion protein comprising sequentially an RBP segment and an uninterrupted target polypeptide, wherein RBP segment comprises at least 178 contiguous amino acids of SEQ ID NO:2, wherein the segment comprises amino acid number 34 (Gly) of SEQ ID NO:2 and amino acid number 211 (Gin) of SEQ ID NO:2. In certain embodiments the expression vector does not encode a signal peptide that targets the fusion protein to periplasm. In some examples an amino acid linker sequence is encoded between the RBP segment and the target protein. In certain examples at least one amino acid sequence tag for purification of the encoded fusion protein is included. In non-limiting embodiments, the target protein may be the only target protein encoded by the expression vector, or in the fusion protein, and in certain embodiments the RBP segment may be the only RBP segment encoded by the expression vector, or in the fusion protein. In certain approaches the fusion protein comprises an amino acid linker sequence, and the linker sequence may optionally comprises a proteolytic cleavage site, such as to liberate the target protein from the fusion protein by cleavage at the proteolytic cleavage site. In certain examples, the fusion protein does not oligomerize in solution with proteins that have the same amino acid sequence of the fusion protein encoded by the expression vector.

[0009] In another aspect the disclosure includes a method of making a recombinant fusion protein. The method comprises providing cells at least some of which comprise an expression vector of this disclosure, and allowing expression of the recombinant fusion protein. The fusion protein can be separated from the cells and if desired purified to any desired degree of purity. The target protein can be separated from the fusion protein by, for example, cleaving the fusion protein using any suitable approach or method, including but not limited to cleavage at a proteolytic cleavage site engineered to separate the RBP and the target protein. In certain approaches a cell culture used to express a fusion protein described herein is prokaryotic cell culture, but eukaryotic cell cultures can also be used. [0010] In another aspect the disclosure comprises a method of making a cell culture that is useful for recombinant protein expression. This method comprises introducing an expression vector into a cell culture. The disclosure accordingly includes such cell cultures, their progeny, and further comprises the media in which any cell culture described herein is cultured in. Also included are cell lysates obtained by lysing any cell or population of cells described herein.

[0011] In another aspect the disclosure provides a kit. The kit can comprise, for example, an expression vector described herein, and may optionally comprise a restriction endonuclease that recognizes a restriction endonuclease recognition site positioned between the RBP and the target protein. The kit can also include printed instructions for using the expression vector to express the fusion protein.

[0012] The disclosure includes any fusion proteins made using a composition, method, and/or kit described herein, and also includes any target polypeptide cleaved from such a fusion protein.

BRIEF DESCRIPTION OF FIGURES

[0013] Figure 1. Schematic representation of resultant fusion protein. The tteRBP tag is shown in red, protein of interest in blue, optional purification tags in green, and optional linker sequences in white. The tteRBP is presented at the N-terminal end of the protein of interest, but it may also be placed at the C-terminal end.

[0014] Figure 2. Schematic of E. coli expression plasmid pRExpress. This is a schematic of representative bacterial expression plasmid that comprises the DNA sequence for the tteRBP tag, functional homologue, fragment, or derivative. It includes a representative promoter (e.g. the T7 promoter shown in cyan), and additional expression-control elements required for the particular expression system being used (e.g. the lacl gene (orange) and lac operator (blue)), the tteRBP, functional homologue, fragment, or derivative expression tag (red), a multiple cloning site containing the sequences for restriction endonucleases (green), a selection element such as antibiotic resistance (e.g. the ampR gene shown in magenta), and an origin of replication to allow the cells to synthesize more plasmids as they grow (black). Each of these elements may be tailored to the different expression systems they are being used in (e.g. using the Aoxl or Aox2 promoters instead of T7 promoter for methanol induction in the model organism Pichia pastor is).

[0015] Figure 3. Full length human p53 gels. Shown is an SDS-PAGE gel of full-length p53 expressed as fusion proteins to either an N-terminal 6x His tag (left) or 6x His-tteRBP tag (right) through a cleavable linker containing the HRV 3C recognition site. Additionally, the gel on the right shows samples taken before and after overnight cleavage with GST-tagged HRC 3C protease. These gels demonstrate a marked increase in soluble expression of the fusion protein. [0016] Figure 4. Shown is an SDS-PAGE gel of whole cell lysates of uninduced BL21

(DE3) with WDR5 expressed alone, or as a tteRBP fusion protein (both proteins contained N- terminal 6xHis tags). Molecular weight standard is the CLEARLY protein ladder (Unstained) (Clontech Laboratories Inc., Mountain View, CA). This figure clearly demonstrates that the fusion protein expresses at substantially higher levels than the unfused WDR5.

[0017] Figure 5. Shown is an SDS-PAGE gel of HRV3C protease purified using our system purified using the GST-tag obtained from a commercial source. Molecular weight standard is the CLEARLY protein ladder (unstained) (Clontech Laboratories Inc., Mountain View, CA). This figure demonstrates that the fusion protein of tteRBP and HRV3C protease can be expressed and purified from E. coli.

DETAILED DESCRIPTION

[0018] Unless defined otherwise herein, all technical and scientific terms used in this disclosure have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure pertains. [0019] Every numerical range given throughout this specification includes its upper and lower values, as well as every narrower numerical range that falls within it, as if such narrower numerical ranges were all expressly written herein.

[0020] Every DNA sequence disclosed herein includes its complementary DNA sequence, and also includes the RNA equivalents thereof. Every DNA and RNA sequence encoding the polypeptides disclosed herein is encompassed by this disclosure, including but not limited to all fusion proteins, and all of the Ribose Binding Protein (RBP) segment of fusion proteins, including but not limited to those comprising N-terminal and/or C-terminal truncations of the RBP segment.

[0021] The present disclosure encompasses compositions and methods for improving production of recombinantly produced protein. In embodiments the disclosure comprises recombinant expression vectors and methods of using them to produce proteins. In general the expression vectors encode at least one fusion protein comprising a segment that includes a polypeptide of interest (also referred to herein as a "target protein") and a segment that comprises a Ribose Binding Protein (RBP) or at least a contiguous portion of an RBP. [0022] In embodiments, the RBP encoded by the expression vector comprises an RBP from a prokaryote, such as an archaea, which may be a thermophilic and/or anaerobic microorganism. In an embodiment, the RBP is from Thermoanaerobacter tengcongensis (T. tengcongensis), which is referred to herein as "tteRBP." In embodiments, the RBP comprises a functional homologue, fragment, or derivative of tteRBP or a segment thereof which retains the capability to enhance production of a fusion protein into which it is inserted. Enhanced protein production means in one embodiment that more of the fusion protein is produced than a value for a suitable reference. In embodiments, the reference can be a value obtained by production of the protein into which the RBP or segment thereof has not been inserted. In embodiments, the disclosure includes increasing production of a recombinant protein by at least 10% relative to a reference, and can comprise increasing production of a recombinant protein by from 10%-80%, inclusive, relative to a reference, or more than 80% relative to a reference. [0023] In embodiments, the RBP comprises an amino acid sequence that is at least 80% similar to SEQ ID NO:2, or to a contiguous segment of SEQ ID NO:2. In embodiments, the RBP comprises an amino acid sequence that is 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQ ID NO:2 or a segment of it, for example, a segment that comprises at least 178 amino acids. Thus, in certain embodiments, an RBP segment of this disclosure comprises variations in sequence relative to SEQ ID NO:2. Such variations can comprise conservative or non- conservative amino acid substitutions, insertions, and deletions. In embodiments, the RBP component of the fusion protein comprises a mutation relative to its naturally occurring sequence. In one embodiment the mutation is a Cysl02Ser alteration. In certain

implementations, the RBP component of a fusion protein lacks a signal peptide, and thus the disclosure also includes entire fusion proteins which lack a signal peptide. The term "lacks a signal peptide" means either the construct may in fact lack the signal peptide sequence, or the signal peptide may simply be modified to lack signal peptide function. In an embodiment, the fusion protein lacks a signal peptide that functions to transport the protein to the periplasm (N- terminal amino acid sequence RKSRILLLLTIFVTSAALILSGCKTNTPNTASTST (SEQ ID NO: 17).

[0024] In embodiments the RBP component of the fusion protein is a segment of a full- length RBP (but lacking a signal sequence). We have also determined if 34 or more amino acids are removed from the N-terminus, or 68 or more amino acids are removed from the C-terminus, the protein loses much of its stability and native structure/function as measured by melting temperature, far UV circular dichroism spectrum, 2D NMR spectrum, and ribose binding ability. Thus, it is considered that a truncation of the first 34 or more N-terminal amino acids, or the last 68 or more C-terminal amino acids of SEQ ID NO:2, exceeds the limits of how much the ends of the tteRBP component can be shortened, yet still function to increase expression and solubility. However, an RBP component of the fusion protein that has shorter truncations of amino acids at its N-terminus, its C-terminus, or at both the N- and C-termini, may still have utility as a solubility and expression tag. Therefore, the disclosure includes fusion proteins which comprise truncations at the N-terminus of the RBP component of from 1-33 amino acids, inclusive and including all integers and all ranges of integers there between, and at the C- terminus of the RBP component of from 1-67 amino acids, inclusive and including all integers and all ranges of integers there between.

[0025] In embodiments, the RBP component of the fusion protein comprises a contiguous segment of SEQ ID NO:2 that includes amino acid number 34 of SEQ ID NO:2 at its N terminus. In embodiments, the RBP component of the fusion protein comprises a contiguous segment of SEQ ID NO:2 that includes the amino acid at position 211 of SEQ ID NO:2 at its C- terminus. In embodiments, the RBP component of the fusion protein comprises a contiguous segment of SEQ ID NO:2 that comprises or consists of a segment of SEQ ID NO:2 having the amino acid at position 34 and the amino acid at position 211 of SEQ ID NO:2 at its N- and C- terminus, respectively. In embodiments, the RBP component of the fusion protein is from 278 to 211 amino acids in length. In one embodiment, the RBP component is at least 244 amino acids in length. In embodiments, the fusion protein comprises a tteRBP component lacking the signaling peptide and comprising amino acids 1-211, 1-259, or 34-278, of SEQ ID NO:2. SEQ ID NO:2 is:

MKEGKTIGL VIS TLNNPFFVTLKNGAEEKAKEL G YKI I VEDSQNDSSKELSNVEDL IQQKVD VLL INP VDSDA WTA IKEANSKNIPVITIDRSANGGDWSHIASDNVKGGEMAAEFIAKALKGKGNWELEGIPGAS AARDRGKGFDEAIAK YPDIKIVAKQAADFDRSKGLSVMENILQAQPKIDAVFAQNDEMALGAIKAIEAANRQGII WGFDGTEDALKAIKEG

KMAA TiAQQPALMGSL GVEMADKYLKGEKiPNFiPAELKL I TKENVQ . The bold italicized amino acids indicate those that have been determined in accordance with this invention to be dispensable for use in the enhanced protein production approaches of this disclosure.

[0026] In embodiments, the fusion proteins do not comprise ubiquitin. In embodiments the fusion proteins do not comprise any segment of ubiquitin that can enhance production of the fusion protein in which the ubiquitin segment is contained, relative to production of an otherwise same fusion protein but in which the ubiquitin segment is not present. In embodiments the fusion proteins do not comprise a ubiquitin-like protein, Apoptosis Stimulating Protein of p53 2 ("ASPP2"), an isoform of ASPP2, or General Control Protein 4 ("GCN4"). In embodiments the fusion proteins of the present disclosure do not bind to one another in solution, and/or do not oligomerize, and/or do not undergo domain swapping with one another and thus do not bind to other of the same or similar fusion proteins in trans, and/or do not bind to one another in cis. In an embodiment, the fusion proteins do not form a network, such as a branched network, or a gel comprising the fusion proteins. In embodiments, fusion proteins of this disclosure retain their native-like structure, which can be determined, for example, using near-UV circular dichroism spectroscopy (CD), electrophoretic mobility shift assay (EMSA), gel-filtration chromatography, or any other suitable approach for determining protein structure. In embodiments, isolated fusion proteins of this disclosure retain their native-like structure. In embodiments, a fusion protein of this disclosure may comprise only a single RBP, even if the RBP is interrupted by a distinct polypeptide sequence. In embodiments a fusion protein of this disclosure can include only one protein of interest, which may be N-terminal to the RBP segment, C-terminal to the RBP segment, or flanked by RBP segments.

[0027] A representative polynucleotide sequence encoding tteRBP is provided in SEQ

ID NO: l . Those skilled in the art will recognize that, due to the redundancy of the genetic code, there are a multitude of polynucleotide sequences that can encode tteRBP, and each of these sequences is included within the scope of this disclosure. This also pertains to the other DNA sequences that encode representative and non-limiting examples of fusion proteins provided by this disclosure as further described in the Examples.

[0028] The polypeptide encoded by the expression vector along with the RBP segment may be any polypeptide of interest. A target polypeptide according to the present disclosure may be any polypeptide required or desired in larger amounts and therefore may be difficult to isolate or purify from other sources. Non-limiting examples of target proteins that can produced by the present methods include mammalian gene products, such as enzymes, cytokines, growth factors, hormones, vaccines, antibodies and the like. In embodiments, overexpressed gene products of the present disclosure include gene products such as erythropoietin, insulin, somatotropin, growth hormone releasing factor, platelet derived growth factor, epidermal growth factor, transforming growth factor a, transforming growth factor 13, epidermal growth factor, fibroblast growth factor, nerve growth factor, insulin-like growth factor I, insulin-like growth factor II, clotting Factor VIII, superoxide dismutase, a-interferon, γ-interferon, interleukin-1, interleukin- 2, interleukin-3, interleukin-4, interleukin-5, interleukin-6, granulocyte colony stimulating factor, multi-lineage colony stimulating activity, granulocyte-macrophage stimulating factor, macrophage colony stimulating factor, T cell growth factor, lymphotoxin and the like. In embodiments overexpressed gene products are human gene products. The present methods can readily be adapted to enhance secretion of any overexpressed gene product which can be used as a vaccine. Overexpressed gene products which can be used as vaccines include any structural, membrane-associated, membrane-bound or secreted gene product of a mammalian pathogen. Mammalian pathogens include viruses, bacteria, single-celled or multi-celled parasites which can infect or attack a mammal. For example, viral vaccines can include vaccines against viruses such as human immunodeficiency virus (HIV), vaccinia, poliovirus, adenovirus, influenza, hepatitis A, hepatitis B, dengue virus, Japanese B encephalitis, Varicella zoster,

cytomegalovirus, hepatitis A, rotavirus, as well as vaccines against viral diseases like measles, yellow fever, mumps, rabies, herpes, influenza, parainfluenza and the like. Bacterial vaccines can include vaccines against bacteria such as Vibrio cholerae, Salmonella typhi, Bordetella pertussis, Streptococcus pneumoniae, Hemophilus influenza, Clostridium tetani,

Corynebacterium diphtheriae, Mycobacterium leprae, R. rickettsii, Shigella, Neisseria gonorrhoeae, Neisseria meningitidis, Coccidioides immitis, Borellia burgdorferi, and the like. A target polypeptide may also comprise sequences; e.g., diagnostically relevant epitopes, from several different proteins constructed to be expressed as a single recombinant polypeptide.

[0029] Variants of the RBP or target protein bearing one or several amino acid substitutions or deletion are also included in this disclosure. The skilled artisan can easily assess whether such variants, e.g., fragments or mutants are appropriate for a method of this disclosure by, for example, using the procedures as described in the Examples.

[0030] As described above, in embodiments the present disclosure provides polypeptides comprising at least one polypeptide domain corresponding to the tteRBP used as an expression tool and at least one polypeptide domain corresponding to the target protein. In embodiments, the tteRBP component is referred to as a solubility and expression tag.

[0031] A representative and non-limiting configuration of a fusion protein of this disclosure is provided in Figure 1 wherein the location of an optional linker polypeptide of 10- 100 amino acid residues is depicted. As the skilled artisan will appreciate, such a linker polypeptide is designed as most appropriate for the intended application, especially in terms of length, flexibility, charge, and hydrophilicity. E.g., in case of a hydrophobic target protein the linker polypeptide may contain an appropriate number of hydrophilic amino acids. In embodiments the present disclosure also relates to fusion proteins which comprise the target polypeptide and one, or two tteRBP- solubility and expression tag or domains thereof and an appropriate peptidic linker sequences between domains. For such applications where the target protein is desired in free form a linker peptide or linker peptides can be used. Such linkers contain an appropriate proteolytic cleavage site. Peptide sequences appropriate for proteolytic cleavage are well-known to the skilled artisan and comprise amongst others, e.g., Ile-Glu-Gly- Arg, cleaved at the carboxy side of the arginine residue by coagulation factor Xa, or Gly -Leu- Pro- Arg-Gly-Ser, a thrombin cleavage site, etc.

[0032] In embodiments the DNA construct of the present disclosure encodes a fusion protein comprising a polypeptide linker in between the polypeptide sequence corresponding to the tteRBP- solubility and expression tag and the polypeptide sequence corresponding to the target protein. Such a DNA sequence coding for a linker, in addition to e.g., providing for a proteolytic cleavage site, may also serve as a polylinker, i.e., it may provide multiple DNA restriction sites to facilitate fusion of the DNA fragments coding for a target protein and a solubility and expression tag domain. [0033] In a further embodiment, the disclosure includes a recombinant DNA molecule, such as an expression vector, encoding a fusion protein, comprising operatively-linked at least one nucleotide sequence coding for a target polypeptide and upstream thereto at least one nucleotide sequence coding for a tteRBP.

[0034] Polynucleotide sequences are operatively-linked when they are placed into a functional relationship with another polynucleotide sequence. For instance, a promoter is operatively-linked to a coding sequence if the promoter affects transcription or expression of the coding sequence. Generally, operatively-linked means that the linked sequences are contiguous and, where necessary to join two protein coding regions, both contiguous and in reading frame. However, it is well known that certain genetic elements, such as enhancers, may be operatively- linked even at a distance, i.e., even if not contiguous. Promoters of the present disclosure may be endogenous or heterologous to the host, and may be constitutive or inducible.

[0035] DNA constructs prepared for introduction into a host typically comprise a replication system recognized by the host, including the intended DNA fragment encoding the desired target fusion peptide, and will can also include transcription and translational initiation regulatory sequences operatively-linked to the polypeptide encoding segment. Expression systems (expression vectors) may include, for example, an origin of replication or autonomously replicating sequence (ARS) and expression control sequences, a promoter, an enhancer and necessary processing information sites, such as ribosome-binding sites, RNA splice sites, polyadenylation sites, transcriptional terminator sequences, and mRNA stabilizing sequences. [0036] The appropriate promoter and other necessary vector sequences are selected so as to be functional in the host. Examples of workable combinations of cell lines and expression vectors include but are not limited to those described Sambrook, J., et al., in "Molecular Cloning: A Laboratory Manual" (1989, 4th edition: 2012)-, Eds. J. Sambrook, E. F. Fritsch and T. Maniatis, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, or Ausubel, F., et al., in "Current Protocols in Molecular Biology" (1987 and periodic updates), Eds. F. Ausubel, R. Brent and K. R. E., Wiley & Sons Verlag, New York; and Metzger, D., et al., Nature 334 (1988) 31-6. Many useful vectors for expression in bacteria, yeast, mammalian, insect, plant or other cells are known in the art and may be obtained from vendors including, but not limited to, Stratagene, New England Biolabs, Promega Biotech, and others. In addition, the construct may be joined to an amplifiable gene (e.g., DHFE) so that multiple copies of the gene may be obtained. [0037] Expression and cloning vectors can contain a selectable marker, a gene encoding a protein necessary for the survival or growth of a host cell transformed with the vector, although such a marker gene may be carried on another polynucleotide sequence co-introduced into the host cell. Only those host cells expressing the marker gene will survive and/or grow under selective conditions. Typical selection genes include but are not limited to those encoding proteins that (a) confer resistance to antibiotics or other toxic substances, e.g., ampicillin, tetracycline, etc.; (b) complement auxotrophic deficiencies; or (c) supply critical nutrients not available from complex media. The choice of the proper selectable marker will depend on the host cell, and appropriate markers for different hosts are known in the art.

[0038] The expression vectors containing the polynucleotides of interest can be introduced into the host cell by any method known in the art. These methods vary depending upon the type of cellular host, including but not limited to transfection employing calcium chloride, rubidium chloride, calcium phosphate, DEAE-dextran, other substances, and infection by viruses. Large quantities of the polynucleotides and polypeptides may be prepared by expressing the polynucleotides in compatible host cells. The most commonly used prokaryotic hosts are strains of Escherichia coli, although other prokaryotes, such as Bacillus subtilis may also be used.

[0039] Construction of a vector according to the present disclosure employs

conventional ligation techniques. Isolated plasmids or DNA fragments are cleaved, tailored, and religated in the form desired to generate the plasmids required. If desired, analysis to confirm correct sequences in the constructed plasmids is performed in a known fashion. Suitable methods for constructions expression vectors, preparing in vitro transcripts, introducing DNA into host cells, and performing analyses for assessing expression and function are known to those skilled in the art. [0040] The DNA construct comprising two solubility and expression tag domains as well as a target polypeptide domain may also contains two linker peptides in between these domains. In order to allow for systematic cloning, the nucleotide sequences coding for these two linker peptide sequences may be different from one another. This difference in nucleotide sequence can result in a difference in the amino-acid sequence of the linker peptides, but the amino acid sequences of the two linker peptides may also be identical. Such identical linker peptide sequences for example are advantageous if the fusion protein comprising two tteRBP- solubility and expression tag domains as well as their target protein domain is to be used in an

immunoassay. [0041] In cases where it is desired to release one or all of the solubility and expression tags out of a fusion protein, the linker peptide can be constructed to comprise a proteolytic cleavage site. Thus, a recombinant DNA molecule, such as an expression vector, encoding a fusion protein comprising at least one polynucleotide sequence coding for a target polypeptide, upstream thereto at least one polynucleotide sequence coding for a tteRBP- solubility and expression tag with the signaling peptide removed, and additionally comprising a nucleic acid sequence coding for a peptidic linker comprising a proteolytic cleavage site, represents a non- limiting embodiment of this invention. In certain embodiments, the expression vector comprises codons optimized for expression in the host cell.

[0042] The recombinant proteins of the inventions can be recovered by conventional methods. Thus, where the host cell is bacterial, such as E. coli it may be lysed physically, chemically or enzymatically and the protein product isolated from the resulting lysate. It is then purified using conventional techniques, including but not necessarily limited to conventional protein isolation techniques such as selective precipitation, adsorption chromatography, and affinity chromatography, including but not limited to a monoclonal antibody affinity column. [0043] In embodiments the fusion proteins comprise a tag for facilitating separation, isolation and/or purification. For example, when the proteins of the present invention are expressed with a histidine tail (HIS tag), they can easily be purified by affinity chromatography using an ion metal affinity chromatography column (IMAC) column.

[0044] In one embodiment, the proteins comprise an affinity peptide, such as a Histidine tail, fused at the carboxy-terminus of the proteins of the invention. In embodiments the His tag comprises between 5 to 8 histidine residues, or at least 4 His residues, or 6 His residues. In embodiments the affinity peptide has adjacent histidine residues, such as at least two, three or four. In an embodiment the protein comprises 6 directly neighboring histidine residues. In another embodiment, the proteins comprise a C-LYTA tag at their carboxy-terminus. Lyta is derived from Streptococcus pneumoniae which synthesize an N-acetyl-L-alanine amidase, amidase LYTA, (coded by the lytA gene {Gene, 43 (1986) page 265-272} an autolysin that specifically degrades certain bonds in the peptidoglycan backbone. The C-terminal domain of the LYTA protein is responsible for the affinity to the choline or to some choline analogues such as DEAE. This property has been exploited for the development of E.coli C-LYTA expressing plasmids useful for expression of fusion proteins. Purification of hybrid proteins containing the C-LYTA fragment at its amino terminus has been described {Biotechnology: 10, (1992) page 795-798}. [0045] When used as part of an expression construct designed for the expression of the coded protein in an appropriate host (e.g. a bacterial expression plasmid in E. Coli, pCDFDuet-1 and pET-23 used with BL21(DE3) in Example 1), the disclosure produces a novel fusion protein, from which the protein of interest can be readily purified, in certain embodiments at substantially higher levels than can be achieved using only the sequence for the protein of interest alone.

[0046] Fusion polypeptides can be purified to high levels (greater than 80%, or greater than 90% pure, as visualized by SDS-PAGE) by undergoing further purification steps. An additional purification step is a Q-Sepharose step that may be operated either before or after the IMAC column to yield highly purified protein. They present a major single band when analyzed by SDS PAGE under reducing conditions, and western blot analysis show less than 5% host cell protein contamination.

[0047] The fusion proteins of the invention may be expressed in unicellular hosts such as prokaryotic and lower eukaryotic organisms, such as yeast and bacteria. In an embodiment the fusion are expressed in E. coli. [0048] In one aspect, the present disclosure relates to a method of producing a fusion protein. The method comprises the steps of culturing a host cell transformed with an expression vector as described above, expression of that fusion protein in the respective host cell and separating the protein from the cell culture. The expression system is demonstrated to function with biochemically distinct target proteins, e.g., p53, cellulase 6B and 5A from Thermobifida fusca and cellulase from Pyrococcus horikoshii, WD-repeat containing protein 5 (WDR5) from Drosophila melanogaster, and actin. As can be readily seen from the Examples of this disclosure, specifically relating to these proteins, the efficient expression systems function and result in high levels of fusion protein produced. Similar findings have been made with a variety of other target proteins expressed as fusion proteins.

[0049] Further, we demonstrate that the target protein comprised in a fusion protein produced according to the present disclosure can be obtained in a native-like structure. Such native-like structure and function, e.g., for p53 and cellulases, has been confirmed by near-UV circular dichroism spectroscopy (CD), electrophoretic mobility shift assay (EMSA), and gel- filtration chromatography. For p53, near-UV CD spectroscopy reveals a folded protein with mixed alpha helix and beta strand character, EMSA reveals high-affinity site-specific binding to DNA including the p53 consensus recognition sequence, and gel-filtration reveals the correct "tetrameric" oligomeric state, which is well known in the art. Cellulases were confirmed native and functional by cellulose filter paper digestion, Avicel digestion, and soluble carboxymethyl cellulose digestion assays, which are well known cellulase activity assays in the art.

[0050] Compositions comprising fusion proteins, or proteins liberated from the tteRBP, are also provided. Such compositions include but are not necessarily limited to compositions that comprise a pharmaceutically acceptable excipient and thus are suitable for human and veterinary prophylactic and/or therapeutic approaches.

[0051] In another embodiment, kits for producing fusion proteins according to this disclosure are provided. The kits can provide one or more expression vectors described herein, as well as printed instructions for using the vectors, and/or for recovering the overexpressed protein.

[0052] The following specific examples are provided to illustrate the invention, but are not intended to be limiting in any way.

EXAMPLE 1

[0053] This Example demonstrates a fusion protein of the present invention that comprises full length p53 expressed in E. coli BL21(DE3).

[0054] Expression Plasmids.

[0055] The full-length human p53 gene (coding sequence for amino acids 1-393) was fused to the 3' end of either an oligonucleotide coding for an N-terminal 6x His tag followed by the human rhinovirus 3C (HRV 3C) protease recognition site (LEVLFN/GP) and placed under the control of a T7 promoter in the pET23 expression vector (EMD Millipore, Billerica, MA), or to the 3' end of an oligonucleotide coding for an N-terminal 6x His tag followed by tteRBP, an linker and a HRV3C protease recognition site and placed under the control of a T7 promoter in the pCDF-Duetl expression vector (EMD Millipore, Billerica, MA). The nucleotide and resultant fusion protein sequences can be seen in Table 1.

[0056] Protein Expression and Partial Purification.

[0057] BL21(DE3) cells made competent by CaCh permeabilization were transformed with the expression plasmids, plated on LB Agar plates containing 50 μg/mL ampicillin (for pET23) or streptomycin (for pCDFDuet-1), and grown at 37 °C for -18 hrs. Isolated colonies were then picked and grown in batch culture (1 L baffled flasks) at 37 °C in LB containing 50 μg/mL appropriate antibiotic with 200 RPM continuous shaking until OD ₆ oo = 0.6. The temperature was then dropped to 20 °C and the cultures induced with 20 mg/L IPTG and grown for ~ 18 hrs. Cells were harvested by centrifugation, resuspended in resuspensi on/wash buffer (20 mM Tris pH 7.2, 300 mM NaCl, 10 mM Imidazole, and 10 mM β-mercaptoethanol), and lysed by incubation with egg white lysozyme and DNAase 1 + 5 mM MgCh on ice for 60 min. Insoluble material was pelleted by centrifugation, and the clarified supernatant loaded on to a Ni ²⁺ -NTA column pre-equilibrated with resuspension/wash buffer. After washing, the sample was eluted with 20 mM Tris pH 7.2, 300 mM NaCl, 250 mM Imidazole, and 10 mM β- mercaptoethanol. Protein-containing fractions were then pooled, dialyzed against 20 mM Tris, 150 mM NaCl, 10 mM β-mercaptoethanol, and the tags removed by incubation with GST- tagged HRV 3C protease (0.05-0.1 mg protease/mg p53) for -18 hrs at 4 °C. Samples were subjected to denaturing, reducing SDS-PAGE (samples prepared by boiling in lx Lamelli Buffer + 10% β-mercaptoethanol for 5 min) and visualized by staining with Coumassie Brilliant Blue.

[0058] Results

[0059] After Ni ²⁺ -NTA chromatography, a band corresponding to the correct molecular weight of 6xHis-HRV3Csite-p53 or the 6xHis-tteRBP-HRV3Csite-p53 fusion protein can be seen. However, the band in the 6xHis-HRV3Csite-p53 lane is faint, and is not significantly more intense than many of the impurities (Fig. 3). In the case of the 6xHis-tteRBP-HRC3Csite-p53, by far the most intense band is the fusion protein (Fig. 3). After cleavage by HRV 3C protease, a band corresponding the correct molecular weight of liberated p53 and the tteRBP tag appear, and the band corresponding to the fusion protein disappears (Fig 3). A gel for the cleaved product for 6xHis-HRV3Csite-p53 is not shown because the tag is too small (-1.4 kDa) to resolve "cleaved" from "uncleaved" protein by SDS-PAGE. After further purification the 6xHis- tteRBP-HRV3Csite-p53 system gave a final yield of 3 mg/L culture of >90% pure p53 by SDS- PAGE and gel filtration (not shown). 6xHis-HRV3Csite-p53 gave an estimated yield of <0.1 mg/L culture -50% pure by SDS-PAGE and gel filtration (not shown). Together, these data demonstrate a >30-fold increase in yield and an 80% increase in purity for recombinant human p53 by employing the modified tteRBP tag in E. coli.

Example 2

[0060] This example demonstrates tteRBP as an expression tag for WD-Repeat Protein 5 (WDR5) from Drosophila melanogaster in E. coli.

[0061] Expression Plasmids

[0062] The coding sequence for WDR5 from Drosophila melanogaster was fused to the

3' end of either an oligonucleotide coding for an N-terminal 6x His tag and placed under the control of a T7 promoter in the pHis-parallell expression vector (NCBI GenBank AF097413.1), or to the 3' end of an oligonucleotide coding for an N-terminal 6x His tag followed by tteRBP, an linker and a HRV3C protease recognition site and placed under the control of a T7 promoter in the pCDF-Duetl expression vector (EMD Millipore, Billerica, MA). The nucleotide and resultant fusion protein sequences can be seen in Table 1.

[0063] Protein Expression and Purification [0064] BL21(DE3) cells made competent by CaCh permeabilization were transformed with the expression plasmids, plated on LB Agar plates containing 50 μg/mL streptomycin for pCDF-Duetl or ampicillinfor pHis-parallell, and grown at 37 °C for -18 hrs. Isolated colonies were then picked and grown in batch culture (5 mL tubes) at 37 °C in LB containing 50 μg/mL streptomycin 50 μg/mL streptomycin for pCDF-Duetl or ampicillinfor pHis-parallell with 200 RPM continuous shaking until OD ₆ oo = 0.6. Cultures were induced with 20 mg/L IPTG and grown at for -18 hrs. Samples taken before induction and after 18 hrs induction were lysed by boiling in cracking buffer (lx lamelli buffer + 4 M Urea + 10% β-mercaptoethanol) for 5 min, and subjected to SDS-PAGE. Whole cell lysates were then visualized by staining with

Coumassie Brilliant Blue.

[0065] Results

[0066] Bands corresponding to the predicted molecular weight of both the untagged and tteRBP tagged proteins can be seen in their respective lanes that are not present in the uninduced sample (Fig. 4). However, the band corresponding to the fusion protein is much more intense, indicating that it expressed at a much higher level than the untagged protein. In combination with other data in this work, this indicates that tteRBP can enhance the expression of many diverse proteins.

Example 3 [0067] This Example demonstrates use of tteRBP as an expression tag in E. coli

BL21(DE3) for the expression of Actin.

[0068] Expression Plasmids

[0069] The full-length human actin gene was fused to the 3' end of an oligonucleotide coding for an N-terminal 6x His tag followed by tteRBP, an linker and a HRV3C protease recognition site and placed under the control of a T7 promoter in the pCDF-Duetl expression vector (EMD Millipore, Billerica, MA). The nucleotide and resultant fusion protein sequences can be seen in Table 1.

[0070] Protein Expression [0071] BL21(DE3) cells made competent by CaCh permeabilization were transformed with the expression plasmids, plated on LB Agar plates containing 50 μg/mL streptomycin, and grown at 37 °C for -18 hrs. Isolated colonies were then picked and grown in batch culture (50 mL unbaffled flasks) at 37 °C in LB containing 50 μg/mL streptomycin with 225 RPM continuous shaking until OD ₆ oo = 0.6. Cultures were then cooled to 20 °C and induced with 20 mg/L IPTG and grown at for ~ 18 hrs. Cells were harvested by centrifugation, resuspended in resuspension/wash buffer (20 mM Tris pH 7.2, 300 mM NaCl, 10 mM Imidazole, and 10 mM β- mercaptoethanol), and lysed by incubation with egg white lysozyme and DNAase 1 + 5 mM MgCh on ice for 60 min. The fusion protein expressed as inclusion bodies, which were pelleted by centrifugation and washed 3 times in buffer and 1 M NaCl. The pellet was then dissolved in 20 mM Tris pH 7.2, 300 mM NaCl, 10 mM Imidazole, 10 mM β-mercaptoethanol + 6 M guanidine-hydrochloride and loaded onto an Ni ²⁺ -NTA column pre-equilibrated with the same buffer. After washing, the sample was eluted with 20 mM Tris pH 7.2, 300 mM NaCl, 250 mM Imidazole, and 10 mM β-mercaptoethanol. Protein-containing fractions were then pooled, and refolded by 20-fold rapid dilution into 20 mM Tris, 150 mM NaCl, 10 mM β-mercaptoethanol. Samples were subjected to denaturing, reducing SDS-PAGE (samples prepared by boiling in lx Lamelli Buffer + 10% β-mercaptoethanol for 5 min) and visualized by staining with Coumassie Brilliant Blue.

[0072] Results

[0073] The resultant protein was soluble and resulted in a single homogenous band by SDS-PAGE. This is a substantial improvement over previous attempts at IPTG-inducible recombinant expression of human actin in E. coli, which has previously been demonstrated to yield little to no soluble protein at these temperatures [Production of human beta actin and a mutant using bacterial expression system with a cold shock vector, Tamura M et al, Protein Expression and Purification (2010)].

Example 4

[0074] This example demonstrates a fusion protein of the present invention that comprises and RBP fusion with HRV3C protease.

[0075] Expression Plasmid

[0076] The sequence for HRV3C protease was fused to the 3' end of an oligonucleotide coding for an N-terminal 6x His tag followed by tteRBP and placed under the control of a T7 promoter in the pCDF-Duetl expression vector (EMD Millipore, Billerica, MA). [0077] Protein Expression and Purification

[0078] BL21(DE3) cells made competent by CaCh permeabilization were transformed with the expression plasmids, plated on LB Agar plates containing 50 μg/mL streptomycin and grown at 37 °C for -18 hrs. Isolated colonies were then picked and grown in batch culture (1 L baffled flasks) at 37 °C in LB containing 50 μg/mL streptomycin with 200 RPM continuous shaking until OD ₆ oo = 0.6. The temperature was then dropped to 18 °C and the cultures induced with 20 mg/L IPTG and grown for ~ 18 hrs. Cells were harvested by centrifugation, resuspended in resuspension/wash buffer (20 mM Tris pH 8.0, 300 mM NaCl, 10 mM Imidazole, and 10 mM β-mercaptoethanol), and lysed by incubation with egg white lysozyme and DNAase 1 + 5 mM MgCh on ice for 60 min. Insoluble material was pelleted by centrifugation, and the clarified supernatant loaded on to a Ni ²⁺ -NTA column pre-equilibrated with resuspension/wash buffer. After washing, the sample was eluted with 20 mM Tris pH 8.0, 300 mM NaCl, 250 mM

Imidazole, and 10 mM β-mercaptoethanol. Protein-containing fractions were then pooled, dialyzed against 20 mM Tris, 10 mM β-mercaptoethanol. Samples were then further purified by Q-sepharose chromatography in the same buffer with a 0-lM NaCl gradient. Samples were subjected to denaturing, reducing SDS-PAGE (samples prepared by boiling in lx Lamelli Buffer + 10% β-mercaptoethanol for 5 min) and visualized by staining with Coumassie Brilliant Blue. Prescission protease (GST-fused HRV3C protease) was obtained from GE Healthcare Life Sciences for comparison.

[0079] Results

[0080] We were able to purify a protein was purified with a molecular weight consistent with the fusion protein, with the only major impurity being a band with a molecular weight consistent with the free-RBP tag (Fig. 5). This protein was purified in yields of >10 mg/L. This demonstrates the use of an embodiment of this disclosure to express and purify proteases in high yield. The results are shown in Figure 5, which depicts an SDS-PAGE gel of HRV3C protease purified using our pRexpress system. The fusion protein included a GST-tag obtained from a commercial source. The molecular weight standard is the CLEARLY protein ladder (unstained) (Clontech Laboratories Inc., Mountain View, CA). Thus, the example demonstrates a fusion protein of tteRBP and HRV3C protease can be expressed and purified from E. coli using a non- limiting embodiment of this disclosure.

Example 5

[0081] This example demonstrates an RBP fusion protein that comprises full length

MDM2, a ubiquitin E3 ligase.

[0082] Expression Plasmid.

[0083] The full-length human MDM2 gene was fused to the 3' end of an oligonucleotide coding for an N-terminal 6x His tag followed by tteRBP, an linker and a HRV3C protease recognition site and placed under the control of a T7 promoter in the pCDF-Duetl expression vector (EMD Millipore, Billerica, MA).

[0084] Protein expression and purification

[0085] BL21(DE3) cells made competent by CaCh permeabilization were transformed with the expression plasmid, plated on LB Agar plates containing 50 μg/mL streptomycin, and grown at 37 °C for -18 hrs. Isolated colonies were then picked and grown in batch culture (1 L baffled flasks) at 37 °C in LB containing 50 μg/mL streptomycin with 200 RPM continuous shaking until OD ₆ oo = 0.6. The temperature was then dropped to 18 °C and the cultures induced with 20 mg/L IPTG and grown for ~ 18 hrs. Cells were harvested by centrifugation, resuspended in resuspension/wash buffer (20 mM Tris pH 8.0, 300 mM NaCl, 10 mM Imidazole, and 10 mM β-mercaptoethanol), and lysed by incubation with egg white lysozyme and DNAase 1 + 5 mM MgCh on ice for 60 min. Insoluble material was pelleted by centrifugation, and the clarified supernatant loaded on to a Ni ²⁺ -NTA column pre-equilibrated with resuspension/wash buffer. After washing, the sample was subjected to on-column tag cleavage with GST-tagged HRV 3C protease (0.05-0.1 mg protease/mg p53) for -18 hrs at 4 °C. The protein was then collected, and samples were subjected to denaturing, reducing SDS-PAGE (samples prepared by boiling in lx Lamelli Buffer + 10% β-mercaptoethanol for 5 min) and visualized by staining with Coumassie Brilliant Blue.

[0086] Results [0087] We were able to purify a protein that migrated at a molecular weight consistent with MDM2. We were able to confirmed its identity by western blot, and also found that this protein bound to full-length p53. Thus, this example demonstrates yet another embodiment of this disclosure in the form of an RBP/MDM2 fusion protein.

Table 1. Representative nucleotide and protein sequences used in this disclosure. In amino acid sequences below, the tteRBP amino acid sequences are italicized, amino acid sequences of proteins of interest are underlined, amino acid sequences of additional purification tags (e.g. 6xHis) show in bold, and amino acid sequences of linkers are shown in plain text (without italics, without underlining, and not it bold). Additionally, protease recognition sequences within linkers are shown with a double underline.

DNA coding sequence of modified tteRBP for use as an expression and solubility tag

(SEQ ID NO:1)

1 ATGAAAGAGG GCAAAACGAT TGGCCTGGTG ATCTCTACCC TGAACAATCC GTTCTTTGTG

61 ACCCTGAAAA ATGGTGCGGA AGAAAAAGCG AAAGAACTGG GTTACAAAAT TATCGTTGAA

121 GATTCGCAAA ATGATTCCTC TAAAGAGCTG TCTAATGTCG AAGATTTGAT TCAACAGAAA

181 GTTGATGTTC TGCTGATCAA TCCGGTGGAT AGCGATGCGG TTGTTACGGC GATTAAAGAA

241 GCGAATAGCA AAAATATCCC GGTTATTACC ATCGATCGCA GCGCGAATGG TGGTGATGTT

301 GTTTCCCATA TCGCCAGCGA TAATGTTAAG GGTGGCGAAA TGGCCGCGGA ATTTATCGCG

361 AAAGCCCTGA AAGGCAAGGG GAATGTTGTG GAACTGGAAG GGATCCCGGG GGCGTCTGCG

421 GCACGTGATC GCGGCAAAGG GTTTGATGAA GCCATTGCTA AGTATCCGGA TATTAAAATC

481 GTTGCAAAGC AGGCGGCGGA TTTTGATCGT TCCAAAGGTC TGTCAGTGAT GGAAAACATC

541 TTGCAAGCCC AGCCGAAAAT TGATGCAGTG TTTGCGCAAA ATGATGAAAT GGCTCTGGGC

601 GCTATCAAAG CCATTGAGGC CGCGAATCGT CAAGGTATTA TTGTTGTGGG CTTTGATGGG

661 ACCGAAGATG CTCTGAAAGC GATTAAAGAA GGGAAAATGG CTGCGACCAT TGCGCAGCAG

721 CCGGCCCTGA TGGGCTCACT GGGTGTGGAG ATGGCTGATA AATACCTGAA AGGTGAAAAA

781 ATTCCGAACT TTATTCCGGC AGAACTGAAA CTCATCACGA AAGAAAATGT GCAG

Amino acid sequence of modified tteRBP for use as an expression and solubility tag

(SEQ ID NO:2)

MKEGKTIGLVISTLNNPFFVTLKNGAEEKAKELGYKIIVEDSQNDSSKELSNVEDLIQQK VD VLL INP VDSDA WTA IKEANSKNI P VI TIDRSANGGD WSHIASDNVKGGEMAAEFIA KALKGKGNWELEGIPGASAARDRGKGFDEAIAKYPDIKIVAKQAADFDRSKGLSVMENI LQAQPKIDAVFAQNDEMALGAIKAIEAANRQGIIWGFDGTEDALKAIKEGKMAATIAQQ PALMGSLGVEMADKYLKGEKIPNFIPAELKLITKENVQ

DNA coding sequence of tteRBP-p53 fusion protein used in Example 1 (SEQ ID NO:3)

1 ATGGGCAGCA GCCATCACCA TCATCACCAC AGCCAGGATC CGAATTCGAG CTCGATGAAA

61 GAGGGCAAAA CGATTGGCCT GGTGATCTCT ACCCTGAACA ATCCGTTCTT TGTGACCCTG

121 AAAAATGGTG CGGAAGAAAA AGCGAAAGAA CTGGGTTACA AAATTATCGT TGAAGATTCG

181 CAAAATGATT CCTCTAAAGA GCTGTCTAAT GTCGAAGATT TGATTCAACA GAAAGTTGAT

241 GTTCTGCTGA TCAATCCGGT GGATAGCGAT GCGGTTGTTA CGGCGATTAA AGAAGCGAAT

301 AGCAAAAATA TCCCGGTTAT TACCATCGAT CGCAGCGCGA ATGGTGGTGA TGTTGTTTCC 361 CATATCGCCA GCGATAATGT TAAGGGTGGC GAAATGGCCG CGGAATTTAT CGCGAAAGCC

421 CTGAAAGGCA AGGGGAATGT TGTGGAACTG GAAGGTATCC CGGGGGCGTC TGCGGCACGT

481 GATCGCGGCA AAGGGTTTGA TGAAGCCATT GCTAAGTATC CGGATATTAA AATCGTTGCA

541 AAGCAGGCGG CGGATTTTGA TCGTTCCAAA GGTCTGTCAG TGATGGAAAA CATCTTGCAA

601 GCCCAGCCGA AAATTGATGC AGTGTTTGCG CAAAATGATG AAATGGCTCT GGGCGCTATC

661 AAAGCCATTG AGGCCGCGAA TCGTCAAGGT ATTATTGTTG TGGGCTTTGA TGGGACCGAA

721 GATGCTCTGA AAGCGATTAA AGAAGGGAAA ATGGCTGCGA CCATTGCGCA GCAGCCGGCC

781 CTGATGGGCT CACTGGGTGT GGAGATGGCT GATAAATACC TGAAAGGTGA AAAAATTCCG

841 AACTTTATTC CGGCAGAACT GAAACTCATC ACGAAAGAAA ATGTGCAGGG TGGAGCGGCA

901 AGCGGGGGTG CCGCGGGTGG CAGCTCTGCG GCGCGCCTGC AGGTCGACAA GCTTGCGGCC

961 GCATTAGAAG TGCTGTTTCA AGGTCCAGGC ATGGAGGAGC CGCAGTCAGA TCCTAGCGTC

1021 GAGCCCCCTC TGAGTCAGGA AACATTTTCA GACCTATGGA AACTACTTCC TGAAAACAAC

1081 GTTCTGTCCC CCTTGCCGTC CCAAGCAATG GATGATTTGA TGCTGTCCCC GGACGATATT

1141 GAACAATGGT TCACTGAAGA CCCAGGTCCA GATGAAGCTC CCAGAATGCC AGAGGCTGCT

1201 CCCCCCGTGG CCCCTGCACC AGCAGCTCCT ACACCGGCGG CCCCTGCACC AGCCCCCTCC

1261 TGGCCCCTGT CATCTTCTGT CCCTTCCCAG AAAACCTACC AGGGCAGCTA CGGTTTCCGT

1321 CTGGGCTTCT TGCATTCTGG GACAGCCAAG TCTGTGACTT GCACGTACTC CCCTGCCCTC

1381 AACAAGATGT TTTGCCAACT GGCCAAGACC TGCCCTGTGC AGCTGTGGGT TGATTCCACA

1441 CCCCCGCCCG GCACCCGCGT CCGCGCCATG GCCATCTACA AGCAGTCACA GCACATGACG

1501 GAGGTTGTGA GGCGCTGCCC CCACCATGAG CGCTGCTCAG ATAGCGATGG TCTGGCCCCT

1561 CCTCAGCATC TTATCCGAGT GGAAGGAAAT TTGCGTGTGG AGTATTTGGA TGACAGAAAC

1621 ACTTTTCGAC ATAGTGTGGT GGTGCCCTAT GAGCCGCCTG AGGTTGGCTC TGACTGTACC

1681 ACCATCCACT ACAACTACAT GTGTAACAGT TCCTGCATGG GCGGCATGAA CCGGAGGCCC

1741 ATCCTCACCA TCATCACACT GGAAGACTCC AGTGGTAATC TACTGGGACG GAACAGCTTT

1801 GAGGTGCGTG TTTGTGCCTG TCCTGGGAGA GACCGGCGCA CAGAGGAAGA GAATCTCCGC

1861 AAGAAAGGGG AGCCTCACCA CGAGCTGCCC CCAGGGAGCA CTAAGCGAGC ACTGCCCAAC

1921 AACACCAGCT CCTCTCCCCA GCCAAAGAAG AAACCACTGG ATGGAGAATA TTTCACCCTT

1981 CAGATCCGTG GGCGTGAGCG CTTCGAGATG TTCCGAGAGC TGAATGAGGC CTTGGAACTC

2041 AAGGATGCCC AGGCTGGGAA GGAGCCAGGG GGGAGCAGGG CTCACTCCAG CCACCTGAAG

2101 TCCAAAAAGG GTCAGTCTAC CTCCCGCCAT AAAAAACTCA TGTTCAAGAC AGAAGGGCCT

2161 GACTCAGACT GAC

Amino acid sequence of the tteRBP-p53 fusion protein used in Example 1 (SEQ ID NO:4)

nGSSKKKmmSQDPNSSSMKEGKTIGLVISTLNNPFFVTLKNGAEEKAKELGYKIIVEDS QNDSSKELSNVEDLIQQKVD VLL INP VDSDA WTA IKEANSKNI P VI TIDRSANGGD WS HIASDNVKGGEMAAEFIAKALKGKGNWELEGIPGASAARDRGKGFDEAIAKYPDIKIVA KQAADFDRSKGLSVMENILQAQPKIDAVFAQNDEMALGAIKAIEAANRQGIIWGFDGTE DALKAIKEGKMAATIAQQPALMGSLGVEMADKYLKGEKIPNFIPAELKLITKENVQGGAA SGGAAGGSSAARLOVDKLAAALEVLFOGPGMEEPOSDPSVEPPLSQETFSDLWKLLPENN VLSPLPSQAMDDLMLSPDDIEQWFTEDPGPDEAPRMPEAAPPVAPAPAAPTPAAPAPAPS WPLSSSVPSOKTYOGSYGFRLGFLHSGTAKSVTCTYSPALNKMFCOLAKTCPVOLWVDST PPPGTRVRAMAIYKOSOHMTEWRRCPHHERCSDSDGLAPPQHLIRVEGNLRVEYLDDRN TFRHSVWPYEPPEVGSDCTTIHYNYMCNSSCMGGMNRRPILTI ITLEDSSGNLLGRNSF EVRVCACPGRDRRTEEENLRKKGEPHHELPPGSTKRALPNNTSSSPOPKKKPLDGEYFTL QIRGRERFEMFRELNEALELKDAQAGKEPGGSRAHSSHLKSKKGQSTSRHKKLMFKTEGP DSD

DNA coding sequence of 6xHis-p53 protein without tteRBP tag used in Example 1 (SEQ

ID NO:5):

1 ATGCACCATC ACCACCATCA CCTGGAAGTT CTGTTCCAGG GGCCCATGGA GGAGCCGCAG

61 TCAGATCCTA GCGTCGAGCC CCCTCTGAGT CAGGAAACAT TTTCAGACCT ATGGAAACTA

121 CTTCCTGAAA ACAACGTTCT GTCCCCCTTG CCGTCCCAAG CAATGGATGA TTTGATGCTG

181 TCCCCGGACG ATATTGAACA ATGGTTCACT GAAGACCCAG GTCCAGATGA AGCTCCCAGA

241 ATGCCAGAGG CTGCTCCCCC CGTGGCCCCT GCACCAGCAG CTCCTACACC GGCGGCCCCT

301 GCACCAGCCC CCTCCTGGCC CCTGTCATCT TCTGTCCCTT CCCAGAAAAC CTACCAGGGC

361 AGCTACGGTT TCCGTCTGGG CTTCTTGCAT TCTGGGACAG CCAAGTCTGT GACTTGCACG

421 TACTCCCCTG CCCTCAACAA GATGTTTTGC CAACTGGCCA AGACCTGCCC TGTGCAGCTG 481 TGGGTTGATT CCACACCCCC GCCCGGCACC CGCGTCCGCG CCATGGCCAT CTACAAGCAG

541 TCACAGCACA TGACGGAGGT TGTGAGGCGC TGCCCCCACC ATGAGCGCTG CTCAGATAGC

601 GATGGTCTGG CCCCTCCTCA GCATCTTATC CGAGTGGAAG GAAATTTGCG TGTGGAGTAT

661 TTGGATGACA GAAACACTTT TCGACATAGT GTGGTGGTGC CCTATGAGCC GCCTGAGGTT

721 GGCTCTGACT GTACCACCAT CCACTACAAC TACATGTGTA ACAGTTCCTG CATGGGCGGC

781 ATGAACCGGA GGCCCATCCT CACCATCATC ACACTGGAAG ACTCCAGTGG TAATCTACTG

841 GGACGGAACA GCTTTGAGGT GCGTGTTTGT GCCTGTCCTG GGAGAGACCG GCGCACAGAG

901 GAAGAGAATC TCCGCAAGAA AGGGGAGCCT CACCACGAGC TGCCCCCAGG GAGCACTAAG

961 CGAGCACTGC CCAACAACAC CAGCTCCTCT CCCCAGCCAA AGAAGAAACC ACTGGATGGA

1021 GAATATTTCA CCCTTCAGAT CCGTGGGCGT GAGCGCTTCG AGATGTTCCG AGAGCTGAAT

1081 GAGGCCTTGG AACTCAAGGA TGCCCAGGCT GGGAAGGAGC CAGGGGGGAG CAGGGCTCAC

1141 TCCAGCCACC TGAAGTCCAA AAAGGGTCAG TCTACCTCCC GCCATAAAAA ACTCATGTTC

1201 AAGACAGAAG GGCCTGACTC AGACTGA

Amino acid sequence of the 6xHis-p53 fusion protein without tteRBP tag used in

Example 1 : (SEQ ID NO:6)

MHHHHHHLEVLFOGPMEEPOSDPSVEPPLSOETFSDLWKLLPENNVLSPLPSQAMDDLML SPDDIEQWFTEDPGPDEAPRMPEAAPPVAPAPAAPTPAAPAPAPSWPLSSSVPSOKTYQG SYGFRLGFLHSGTAKSVTCTYSPALNKMFCOLAKTCPVOLWVDSTPPPGTRVRAMAIYKO SOHMTEWRRCPHHERCSDSDGLAPPOHLIRVEGNLRVEYLDDRNTFRHSVWPYEPPEV GSDCTTIHYNYMCNSSCMGGMNRRPILTI ITLEDSSGNLLGRNSFEVRVCACPGRDRRTE EENLRKKGEPHHELPPGSTKRALPNNTSSSPOPKKKPLDGEYFTLOIRGRERFEMFRELN EALELKDAQAGKEPGGSRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD

DNA coding sequence of 6xHis-WDR5 fusion protein used in Example 2 (SEQ ID NO:7)

1 ATGTCGTACT ACCATCACCA TCACCATCAC GATTACGATA TCCCAACGAC CGAAAACCTG

61 TATTTTCAGG GCGCCATGGA TATGGTGCCC ATCGGAGCCG TGCACGGCGG CCATCCCGGC

121 GTAGTGCATC CGCCACAGCA ACCACTGCCC ACGGCGCCCA GCGGCCCAAA CTCGCTGCAG

181 CCGAACTCGG TGGGCCAGCC GGGGGCCACC ACCTCCTCGA ACAGCAGCGC CTCCAACAAG

241 AGCTCGCTAT CCGTCAAGCC CAACTACACG CTCAAGTTCA CGCTGGCCGG GCACACCAAG

301 GCGGTGTCGG CGGTCAAGTT CAGTCCGAAT GGCGAGTGGC TGGCCAGCTC CTCCGCTGAT

361 AAACTAATCA AAATCTGGGG AGCATACGAT GGCAAGTTCG AGAAGACCAT TTCGGGCCAC

421 AAGCTGGGCA TCAGCGATGT GGCCTGGAGC TCAGACTCGC GACTCCTCGT GAGCGGCAGT

481 GATGACAAGA CGCTCAAGGT CTGGGAGCTG AGCACCGGGA AGAGCTTGAA AACTCTGAAG

541 GGCCACAGCA ACTATGTGTT CTGCTGCAAC TTTAATCCGC AGTCCAATCT GATCGTCTCC

601 GGCAGCTTCG ACGAGAGCGT TCGCATATGG GATGTGCGCA CCGGCAAGTG TCTGAAGACT

661 CTACCCGCCC ATTCCGATCC CGTTTCGGCG GTACATTTCA ATCGCGACGG ATCGCTGATC

721 GTGAGCAGCA GCTACGACGG CCTCTGTCGC ATATGGGACA CGGCCAGTGG ACAGTGCTTG

781 AAAACCCTGA TCGACGACGA CAATCCGCCC GTCAGCTTTG TAAAGTTCTC GCCCAATGGC

841 AAGTACATTT TGGCCGCCAC GCTGGATAAT ACGCTCAAGT TGTGGGACTA CTCGAAGGGC

901 AAGTGCCTGA AGACGTATAC GGGTCACAAG AATGAGAAGT ACTGCATATT CGCCAACTTC

961 TCGGTGACGG GAGGAAAGTG GATCGTGAGT GGCAGCGAGG ACAACATGGT CTACATTTGG

1021 AATCTGCAGA GCAAGGAGGT GGTGCAAAAG CTGCAGGGAC ACACCGATAC CGTTCTGTGC

1081 ACCGCCTGCC ATCCCACGGA GAACATCATT GCTTCCGCGG CGCTCGAGAA CGACAAGACC

1141 ATCAAGCTGT GGAAGTCGGA TACATAG

Amino acid sequence of 6xHis-WDR5 fusion protein used in Example 2 (SEQ ID NO:8)

MSYYHHHHHHDYDIPTTENLYFOGAMDMVPIGAVHGGHPGWHPPOOPLPTAPSGPNS LO PNSVGQPGATTSSNSSASNKSSLSVKPNYTLKFTLAGHTKAVSAVKFSPNGEWLASSSAD KLIKIWGAYDGKFEKTISGHKLGISDVAWSSDSRLLVSGSDDKTLKVWELSTGKSLKTLK GHSNYVFCCNFNPOSNLIVSGSFDESVRIWDVRTGKCLKTLPAHSDPVSAVHFNRDGSLI VSSSYDGLCRIWDTASGQCLKTLIDDDNPPVSFVKFSPNGKYILAATLDNTLKLWDYSKG KCLKTYTGHKNEKYCIFANFSVTGGKWIVSGSEDNMVYIWNLOSKEWOKLQGHTDTVLC TACHPTENI IASAALENDKTIKLWKSDT DNA coding sequence of 6xHis-tteRBP-WDR5 fusion protein used in Example 3 (SEQ ID NO:9)

1 ATGGGCAGCA GCCATCACCA TCATCACCAC AGCCAGGATC CGAATTCGAG CTCGATGAAA 61 GAGGGCAAAA CGATTGGCCT GGTGATCTCT ACCCTGAACA ATCCGTTCTT TGTGACCCTG 121 AAAAATGGTG CGGAAGAAAA AGCGAAAGAA CTGGGTTACA AAATTATCGT TGAAGATTCG 181 CAAAATGATT CCTCTAAAGA GCTGTCTAAT GTCGAAGATT TGATTCAACA GAAAGTTGAT 241 GTTCTGCTGA TCAATCCGGT GGATAGCGAT GCGGTTGTTA CGGCGATTAA AGAAGCGAAT 301 AGCAAAAATA TCCCGGTTAT TACCATCGAT CGCAGCGCGA ATGGTGGTGA TGTTGTTTCC 361 CATATCGCCA GCGATAATGT TAAGGGTGGC GAAATGGCCG CGGAATTTAT CGCGAAAGCC 421 CTGAAAGGCA AGGGGAATGT TGTGGAACTG GAAGGTATCC CGGGGGCGTC TGCGGCACGT 481 GATCGCGGCA AAGGGTTTGA TGAAGCCATT GCTAAGTATC CGGATATTAA AATCGTTGCA 541 AAGCAGGCGG CGGATTTTGA TCGTTCCAAA GGTCTGTCAG TGATGGAAAA CATCTTGCAA 601 GCCCAGCCGA AAATTGATGC AGTGTTTGCG CAAAATGATG AAATGGCTCT GGGCGCTATC 661 AAAGCCATTG AGGCCGCGAA TCGTCAAGGT ATTATTGTTG TGGGCTTTGA TGGGACCGAA 721 GATGCTCTGA AAGCGATTAA AGAAGGGAAA ATGGCTGCGA CCATTGCGCA GCAGCCGGCC 781 CTGATGGGCT CACTGGGTGT GGAGATGGCT GATAAATACC TGAAAGGTGA AAAAATTCCG 841 AACTTTATTC CGGCAGAACT GAAACTCATC ACGAAAGAAA ATGTGCAGGG TGGAGCGGCA 901 AGCGGGGGTG CCGCGGGTGG CAGCTCTGCG GCCGCATTAG AAGTGCTGTT TCAAGGTCCA 961 GGCATGGTGC CCATCGGAGC CGTGCACGGC GGCCATCCCG GCGTAGTGCA TCCGCCACAG 1021 CAACCACTGC CCACGGCGCC CAGCGGCCCA AACTCGCTGC AGCCGAACTC GGTGGGCCAG 1081 CCGGGGGCCA CCACCTCCTC GAACAGCAGC GCCTCCAACA AGAGCTCGCT ATCCGTCAAG 1141 CCCAACTACA CGCTCAAGTT CACGCTGGCC GGGCACACCA AGGCGGTGTC GGCGGTCAAG 1201 TTCAGTCCGA ATGGCGAGTG GCTGGCCAGC TCCTCCGCTG ATAAACTAAT CAAAATCTGG

1261 GGAGCATACG ATGGCAAGTT CGAGAAGACC ATTTCGGGCC ACAAGCTGGG CATCAGCGAT 1321 GTGGCCTGGA GCTCAGACTC GCGACTCCTC GTGAGCGGCA GTGATGACAA GACGCTCAAG

1381 GTCTGGGAGC TGAGCACCGG GAAGAGCTTG AAAACTCTGA AGGGCCACAG CAACTATGTG

1441 TTCTGCTGCA ACTTTAATCC GCAGTCCAAT CTGATCGTCT CCGGCAGCTT CGACGAGAGC

1501 GTTCGCATAT GGGATGTGCG CACCGGCAAG TGTCTGAAGA CTCTACCCGC CCATTCCGAT 1561 CCCGTTTCGG CGGTACATTT CAATCGCGAC GGATCGCTGA TCGTGAGCAG CAGCTACGAC 1621 GGCCTCTGTC GCATATGGGA CACGGCCAGT GGACAGTGCT TGAAAACCCT GATCGACGAC 1681 GACAATCCGC CCGTCAGCTT TGTAAAGTTC TCGCCCAATG GCAAGTACAT TTTGGCCGCC

1741 ACGCTGGATA ATACGCTCAA GTTGTGGGAC TACTCGAAGG GCAAGTGCCT GAAGACGTAT

1801 ACGGGTCACA AGAATGAGAA GTACTGCATA TTCGCCAACT TCTCGGTGAC GGGAGGAAAG 1861 TGGATCGTGA GTGGCAGCGA GGACAACATG GTCTACATTT GGAATCTGCA GAGCAAGGAG 1921 GTGGTGCAAA AGCTGCAGGG ACACACCGAT ACCGTTCTGT GCACCGCCTG CCATCCCACG 1981 GAGAACATCA TTGCTTCCGC GGCGCTCGAG AACGACAAGA CCATCAAGCT GTGGAAGTCG 2041 GATACATAG

Amino acid sequence sequence of 6xHis-tteRBP-WDR5 fusion protein used in Example 2 (SEQ ID NO:10)

nGSSKKKmmSQDPNSSSMKEGKTIGLVISTLNNPFFVTLKNGAEEKAKELGYKIIVEDS QNDSSKELSNVEDLIQQKVD VLL INP VDSDA WTA IKEANSKNI P VI TIDRSANGGD WS HIASDNVKGGEMAAEFIAKALKGKGNWELEGIPGASAARDRGKGFDEAIAKYPDIKIVA KQAADFDRSKGLSVMENILQAQPKIDAVFAQNDEMALGAIKAIEAANRQGIIWGFDGTE DALKAIKEGKMAATIAQQPALMGSLGVEMADKYLKGEKIPNFIPAELKLITKENVQGGAA SGGAAGGSSAAALEVLFOGPGMVPIGAVHGGHPGWHPPOOPLPTAPSGPNSLQPNSVGO PGATTSSNSSASNKSSLSVKPNYTLKFTLAGHTKAVSAVKFSPNGEWLASSSADKLIKIW GAYDGKFEKTISGHKLGISDVAWSSDSRLLVSGSDDKTLKVWELSTGKSLKTLKGHSNYV FCCNFNPQSNLIVSGSFDESVRIWDVRTGKCLKTLPAHSDPVSAVHFNRDGSLIVSSSYD GLCRIWDTASGQCLKTLIDDDNPPVSFVKFSPNGKYILAATLDNTLKLWDYSKGKCLKTY AALENDKTIKLWKSDT

Coding nucleotide sequence for tteRBP-actin fusion used in Example 3 (SEQ ID NO: 11 ):

1 ATGGGCAGCA GCCATCACCA TCATCACCAC AGCCAGGATC CGAATTCGAG CTCGATGAAA 61 GAGGGCAAAA CGATTGGCCT GGTGATCTCT ACCCTGAACA ATCCGTTCTT TGTGACCCTG

121 AAAAATGGTG CGGAAGAAAA AGCGAAAGAA CTGGGTTACA AAATTATCGT TGAAGATTCG

181 CAAAATGATT CCTCTAAAGA GCTGTCTAAT GTCGAAGATT TGATTCAACA GAAAGTTGAT

241 GTTCTGCTGA TCAATCCGGT GGATAGCGAT GCGGTTGTTA CGGCGATTAA AGAAGCGAAT

301 AGCAAAAATA TCCCGGTTAT TACCATCGAT CGCAGCGCGA ATGGTGGTGA TGTTGTTTCC

361 CATATCGCCA GCGATAATGT TAAGGGTGGC GAAATGGCCG CGGAATTTAT CGCGAAAGCC

421 CTGAAAGGCA AGGGGAATGT TGTGGAACTG GAAGGTATCC CGGGGGCGTC TGCGGCACGT

481 GATCGCGGCA AAGGGTTTGA TGAAGCCATT GCTAAGTATC CGGATATTAA AATCGTTGCA

541 AAGCAGGCGG CGGATTTTGA TCGTTCCAAA GGTCTGTCAG TGATGGAAAA CATCTTGCAA

601 GCCCAGCCGA AAATTGATGC AGTGTTTGCG CAAAATGATG AAATGGCTCT GGGCGCTATC

661 AAAGCCATTG AGGCCGCGAA TCGTCAAGGT ATTATTGTTG TGGGCTTTGA TGGGACCGAA

721 GATGCTCTGA AAGCGATTAA AGAAGGGAAA ATGGCTGCGA CCATTGCGCA GCAGCCGGCC

781 CTGATGGGCT CACTGGGTGT GGAGATGGCT GATAAATACC TGAAAGGTGA AAAAATTCCG

841 AACTTTATTC CGGCAGAACT GAAACTCATC ACGAAAGAAA ATGTGCAGGG TGGAGCGGCA

901 AGCGGGGGTG CCGCGGGTGG CAGCTCTGCG GCCGCATTAG AAGTGCTGTT TCAAGGTCCA

961 GGCATGGATT CTGAGGTTGC TGCTTTGGTT ATTGATAACG GTTCTGGTAT GTGTAAAGCC

1021 GGTTTTGCCG GTGACGACGC TCCTCGTGCT GTCTTCCCAT CTATCGTCGG TAGACCAAGA

1081 CACCAAGGTA TCATGGTCGG TATGGGTCAA AAAGACTCCT ACGTTGGTGA TGAAGCTCAA

1141 TCCAAGAGAG GTATCTTGAC TTTACGTTAC CCAATTGAAC ACGGTATTGT CACCAACTGG

1201 GACGATATGG AAAAGATCTG GCATCATACC TTCTACAACG AATTGAGAGT TGCCCCAGAA

1261 GAACACCCTG TTCTTTTGAC TGAAGCTCCA ATGAACCCTA AATCAAACAG AGAAAAGATG

1321 ACTCAAATTA TGTTTGAAAC TTTCAACGTT CCAGCCTTCT ACGTTTCCAT CCAAGCCGTT

1381 TTGTCCTTGT ACTCTTCCGG TAGAACTACT GGTATTGTTT TGGATTCCGG TGATGGTGTT

1441 ACTCACGTCG TTCCAATTTA CGCTGGTTTC TCTCTACCTC ACGCCATTTT GAGAATCGAT

1501 TTGGCCGGTA GAGATTTGAC TGACTACTTG ATGAAGATCT TGAGTGAACG TGGTTACTCT

1561 TTCTCCACCA CTGCTGAAAG AGAAATTGTC CGTGACATCA AGGAAAAACT ATGTTACGTC

1621 GCCTTGGACT TCGAACAAGA AATGCAAACC GCTGCTCAAT CTTCTTCAAT TGAAAAATCC

1681 TACGAACTTC CAGATGGTCA AGTCATCACT ATTGGTAACG AAAGATTCAG AGCCCCAGAA

1741 GCTTTGTTCC ATCCTTCTGT TTTGGGTTTG GAATCTGCCG GTATTGACCA AACTACTTAC

1801 AACTCCATCA TGAAGTGTGA TGTCGATGTC CGTAAGGAAT TATACGGTAA CATCGTTATG

1861 TCCGGTGGTA CCACCATGTT CCCAGGTATT GCCGAAAGAA TGCAAAAGGA AATCACCGCT

1921 TTGGCTCCAT CTTCCATGAA GGTCAAGATC ATTGCTCCTC CAGAAAGAAA GTACTCCGTC

1981 TGGATTGGTG GTTCTATCTT GGCTTCTTTG ACTACCTTCC AACAAATGTG GATCTCAAAA

2041 CAAGAATACG ACGAAAGTGG TCCATCTATC GTTCACCACA AGTGTTTCTA A

Amino acid sequence for tteRBP-actin fusion used in Example 3 (SEQ ID NO: 12) nGSSKKKmmSQDPNSSSMKEGKTIGLVISTLNNPFFVTLKNGAEEKAKELGYKIIVEDS QNDSSKELSNVEDLIQQKVD VLL INP VDSDA WTA IKEANSKNI P VI TIDRSANGGD WS HIASDNVKGGEMAAEFIAKALKGKGNWELEGIPGASAARDRGKGFDEAIAKYPDIKIVA KQAADFDRSKGLSVMENILQAQPKIDAVFAQNDEMALGAIKAIEAANRQGIIWGFDGTE DALKAIKEGKMAATIAQQPALMGSLGVEMADKYLKGEKIPNFIPAELKLITKENVQGGAA SGGAAGGSSAAALEVLFOGPGMDSEVAALVIDNGSGMCKAGFAGDDAPRAVFPSIVGRPR HQGIMVGMGOKDSYVGDEAQSKRGILTLRYPIEHGIVTNWDDMEKIWHHTFYNELRVAPE EHPVLLTEAPMNPKSNREKMTOIMFETFNVPAFYVS IQAVLSLYSSGRTTGIVLDSGDGV THWPIYAGFSLPHAILRIDLAGRDLTDYLMKILSERGYSFSTTAERE IVRDI KEKLCYV ALDFEOEMQTAAOSSS IEKSYELPDGOVITIGNERFRAPEALFHPSVLGLESAGIDQTTY NS IMKCDVDVRKELYGNIVMSGGTTMFPGIAERMQKE ITALAPSSMKVKI IAPPERKYSV WIGGS ILASLTTFOOMWI SKOEYDESGPS IVHHKCF

RBP/ HRV3C Fusion Protein Amino Acid Sequence (SEQ ID NO:13): nGSSKKKKKKSQOPNSSSMKEGKTIGLVISTLNNPFFVTLKNGAEEKAKELGYKIIVEDS QNDSSKELSNVEDL IQQKVD VLL INP VDSDA WTA IKEANSKNI P VI TIDRSANGGD WS HIASDNVKGGEMAAEFIAKALKGKGNWELEGIPGASAARDRGKGFDEAIAKYPDIKIVA KQAADFDRSKGLSVMENILQAQPKIDAVFAQNDEMALGAIKAIEAANRQGIIWGFDGTE DALKAIKEGKMAATIAQQPALMGSLGVEMADKYLKGEKIPNFIPAELKLITKENVQGGAA SGGAAGGSSAAAGGPNTEFALSLLRKNIMTITTSKGEFTGLGIHDRVCVI PTHAQPGDDV LVNGQKIRVKDKYKLVDPENINLELTVLTLDRNEKFRDIRGFI SEDLEGVDATLWHSNN FTNTILEVGPVTMAGLINLSSTPTNRMIRYDYATKTGQCGGVLCATGKI FGIHVGGNGRO GFSAQLKKQYFVEKQ

RBP/ HRV3C Fusion Protein DNA coding sequence (SEQ ID NO:14)

1 ATGGGCAG CAGCCATCAC CATCATCACC ACAGCCAGGA TCCGAATTCG

51 AGCTCGATGA AAGAGGGCAA AACGATTGGC CTGGTGATCT CTACCCTGAA

101 CAATCCGTTC TTTGTGACCC TGAAAAATGG TGCGGAAGAA AAAGCGAAAG

151 AACTGGGTTA CAAAATTATC GTTGAAGATT CGCAAAATGA TTCCTCTAAA

2 01 GAGCTGTCTA ATGTCGAAGA TTTGATTCAA CAGAAAGTTG ATGTTCTGCT

251 GATCAATCCG GTGGATAGCG ATGCGGTTGT TACGGCGATT AAAGAAGCGA

3 01 AT AG C AAAAA TATCCCGGTT ATTACCATCG ATCGCAGCGC GAATGGTGGT

351 GATGTTGTTT CCCATATCGC CAGCGATAAT GTTAAGGGTG GCGAAATGGC

4 01 CGCGGAATTT ATCGCGAAAG CCCTGAAAGG CAAGGGGAAT GTTGTGGAAC

451 TGGAAGGTAT CCCGGGGGCG TCTGCGGCAC GTGATCGCGG CAAAGGGTTT

501 GATGAAGCCA TTGCTAAGTA TCCGGATATT AAAATCGTTG CAAAGCAGGC

551 GGCGGATTTT GATCGTTCCA AAGGTCTGTC AGTGATGGAA AACATCTTGC

6 01 AAGCCCAGCC GAAAATTGAT GCAGTGTTTG CGCAAAATGA TGAAATGGCT

651 CTGGGCGCTA TCAAAGCCAT TGAGGCCGCG AATCGTCAAG GTATTATTGT

701 TGTGGGCTTT GATGGGACCG AAGATGCTCT GAAAGCGATT AAAGAAGGGA

751 AAATGGCTGC GACCATTGCG CAGCAGCCGG CCCTGATGGG CTCACTGGGT

8 01 GTGGAGATGG CTGATAAATA CCTGAAAGGT GAAAAAATTC CGAACTTTAT

851 TCCGGCAGAA CTGAAACTCA TCACGAAAGA AAATGTGCAG GGTGGAGCGG

901 CAAGCGGGGG TGCCGCGGGT GGCAGCTCTG CGGCCGCAGG CGGACCAAAC

951 ACAGAATTTG CACTATCCCT GTTAAGGAAA AACATAATGA CTATAACAAC

1001 CTCAAAGGGA GAGTTCACAG GGTTAGGCAT ACATGATCGT GTCTGTGTGA

1051 TACCCACACA CGCACAGCCT GGTGATGATG TACTAGTGAA TGGTCAGAAA

1101 ATTAGAGTTA AGGATAAGTA CAAATTAGTA GAT CC AG AG A ACATTAATCT

1151 AGAGCTTACA GTGTTGACTT TAGATAGAAA TGAAAAATTC AG AG AT AT C A

12 01 GGGGATTTAT ATCAGAAGAT CTAGAAGGTG TGGATGCCAC TTTGGTAGTA

1251 CATTCAAATA ACTTTACCAA CACTATCTTA GAAGTTGGCC CTGTAACAAT 1301 GGCAGGACTT ATTAATTTGA GTAGCACCCC CACTAACAGA ATGATTCGTT

1351 ATGATTATGC AACAAAAACT GGGCAGTGTG GAGGTGTGCT GTGTGCTACT

1401 GGTAAGATCT TTGGTATTCA TGTTGGCGGT AATGGAAGAC AAGGATTTTC 1451 AGCTCAACTT AAAAAACAAT ATTTTGTAGA GAAACAATAA

RBP/MDM2 fusion protein amino acid sequence (SEQ ID NO:15):

MGSSKKKKKKSQOPNSSSMKEGKTIGLVISTLNNPFFVTLKNGAEEKAKE LGYKIIVEDSQNDSSKELSNVEDLIQQKVDVLLINPVDSDAWTAIKEAN SKNIPVITIDRSANGGDWSHIASDNVKGGEMAAEFIAKALKGKGNWEL EGIPGASAARDRGKGFDEAIAKYPDIKIVAKQAADFDRSKGLSVMENILQ AQPKIDAVFAQNDEMALGAIKAlEAANRQGIIWGFDGTEDALKAIKEGK

MAATIAQQPALMGSLGVEMADKYLKGEKIPNFIPAELKLITKENVQGGAA SGGAAGGSSAARLOVDKLAAALEVLFOGPGMCNTNMSVPTDGAVTTSOIP ASEQETLVRPKPLLLKLLKSVGAOKDTYTMKEVLFYLGQYIMTKRLYDEK OOHIVYCSNDLLGDLFGVPSFSVKEHRKIYTMIYRNLVWNOOESSDSGT SVSENRCHLEGGSDQKDLVQELQEEKPSSSHLVSRPSTSSRRRAISETEE NSDELSGERQRKRHKSDSISLSFDESLALCVIREICCERSSSSESTGTPS NPDLDAGVSEHSGDWLDODSVSDOFSVEFEVESLDSEDYSLSEEGOELSD EDDEVYQVTVYQAGESDTDSFEEDPEISLADYWKCTSCNEMNPPLPSHCN RCWALRENWLPEDKGKDKGEISEKAKLENSTQAEEGFDVPDCKKTIVNDS RESCVEENDDKITOASOSOESEDYSOPSTSSSI IYSSOEDVKEFEREETO DKEESVESSLPLNAIEPCVICQGRPKNGCIVHGKTGHLMACFTCAKKLKK RNKPCPVCRQPIQMIVLTYFP

RBP/MDM2 fusion protein Fusion protein coding nucleotide sequence (SEQ ID NO:16)

1 CCATGGGCAG CAGCCATCAC CATCATCACC ACAGCCAGGA TCCGAATTCG

51 AGCTCGATGA AAGAGGGCAA AACGATTGGC CTGGTGATCT CTACCCTGAA

101 CAATCCGTTC TTTGTGACCC TGAAAAATGG TGCGGAAGAA AAAGCGAAAG

151 AACTGGGTTA CAAAATTATC GTTGAAGATT CGCAAAATGA TTCCTCTAAA

201 GAGCTGTCTA ATGTCGAAGA TTTGATTCAA CAGAAAGTTG ATGTTCTGCT

251 GATCAATCCG GTGGATAGCG ATGCGGTTGT TACGGCGATT AAAGAAGCGA

301 ATAGCAAAAA TATCCCGGTT ATTACCATCG ATCGCAGCGC GAATGGTGGT

351 GATGTTGTTT CCCATATCGC CAGCGATAAT GTTAAGGGTG GCGAAATGGC

401 CGCGGAATTT ATCGCGAAAG CCCTGAAAGG CAAGGGGAAT GTTGTGGAAC

451 TGGAAGGTAT CCCGGGGGCG TCTGCGGCAC GTGATCGCGG CAAAGGGTTT

501 GATGAAGCCA TTGCTAAGTA TCCGGATATT AAAATCGTTG CAAAGCAGGC

551 GGCGGATTTT GATCGTTCCA AAGGTCTGTC AGTGATGGAA AACATCTTGC

601 AAGCCCAGCC GAAAATTGAT GCAGTGTTTG CGCAAAATGA TGAAATGGCT

651 CTGGGCGCTA TCAAAGCCAT TGAGGCCGCG AATCGTCAAG GTATTATTGT

701 TGTGGGCTTT GATGGGACCG AAGATGCTCT GAAAGCGATT AAAGAAGGGA

751 AAATGGCTGC GACCATTGCG CAGCAGCCGG CCCTGATGGG CTCACTGGGT

801 GTGGAGATGG CTGATAAATA CCTGAAAGGT GAAAAAATTC CGAACTTTAT

851 TCCGGCAGAA CTGAAACTCA TCACGAAAGA AAATGTGCAG GGTGGAGCGG

901 CAAGCGGGGG TGCCGCGGGT GGCAGCTCTG CGGCGCGCCT GCAGGTCGAC

951 AAGCTTGCGG CCGCATTAGA AGTGCTGTTT CAAGGTCCAG GCATGTGCAA

1001 TACCAACATG TCTGTACCTA CTGATGGTGC TGTAACCACC TCACAGATTC

1051 CAGCTTCGGA ACAAGAGACC CTGGTTAGAC CAAAGCCATT GCTTTTGAAG

1101 TTATTAAAGT CTGTTGGTGC ACAAAAAGAC ACTTATACTA TGAAAGAGGT

1151 TCTTTTTTAT CTTGGCCAGT ATATTATGAC TAAACGATTA TATGATGAGA 1201 AGCAACAACA TATTGTATAT TGTTCAAATG ATCTTCTAGG AGATTTGTTT

1251 GGCGTGCCAA GCTTCTCTGT GAAAGAGCAC AGGAAAATAT ATACCATGAT

1301 CTACAGGAAC TTGGTAGTAG TCAATCAGCA GGAATCATCG GACTCAGGTA

1351 CATCTGTGAG TGAGAACAGG TGTCACCTTG AAGGTGGGAG TGATCAAAAG

1401 GACCTTGTAC AAGAGCTTCA GGAAGAGAAA CCTTCATCTT CACATTTGGT

1451 TTCTAGACCA TCTACCTCAT CTAGAAGGAG AGCAATTAGT GAGACAGAAG

1501 AAAATTCAGA TGAATTATCT GGTGAACGAC AAAGAAAACG CCACAAATCT

1551 GATAGTATTT CCCTTTCCTT TGATGAAAGC CTGGCTCTGT GTGTAATAAG

1601 GGAGATATGT TGTGAAAGAA GCAGTAGCAG TGAATCTACA GGGACGCCAT

1651 CGAATCCGGA TCTTGATGCT GGTGTAAGTG AACATTCAGG TGATTGGTTG

1701 GATCAGGATT CAGTTTCAGA TCAGTTTAGT GTAGAATTTG AAGTTGAATC

1751 TCTCGACTCA GAAGATTATA GCCTTAGTGA AGAAGGACAA GAACTCTCAG

1801 ATGAAGATGA TGAGGTATAT CAAGTTACTG TGTATCAGGC AGGGGAGAGT

1851 GATACAGATT CATTTGAAGA AGATCCTGAA ATTTCCTTAG CTGACTATTG

1901 GAAATGCACT TCATGCAATG AAATGAATCC CCCCCTTCCA TCACATTGCA

1951 ACAGATGTTG GGCCCTTCGT GAGAATTGGC TTCCTGAAGA TAAAGGGAAA

2001 GATAAAGGGG AAATCTCTGA GAAAGCCAAA CTGGAAAACT CAACACAAGC

2051 TGAAGAGGGC TTTGATGTTC CTGATTGTAA AAAAACTATA GTGAATGATT

2101 CCAGAGAGTC ATGTGTTGAG GAAAATGATG ATAAAATTAC ACAAGCTTCA

2151 CAATCACAAG AAAGTGAAGA CTATTCTCAG CCATCAACTT CTAGTAGCAT

2201 TATTTATAGC AGCCAAGAAG ATGTGAAAGA GTTTGAAAGG GAAGAAACCC

2251 AAGACAAAGA AGAGAGTGTG GAATCTAGTT TGCCCCTTAA TGCCATTGAA

2301 CCTTGTGTGA TTTGTCAAGG TCGACCTAAA AATGGTTGCA TTGTCCATGG

2351 CAAAACAGGA CATCTTATGG CCTGCTTTAC ATGTGCAAAG AAGCTAAAGA

2401 AAAGGAATAA GCCCTGCCCA GTATGTAGAC AACCAATTCA AATGATTGTG

2451 CTAACTTATT TCCCCTAGCT CGAGTCTGGT AAAGAAACCG CTGCTGCGAA

2501 ATTTGAACGC CAGCACATGG ACTCGTCTAC TAGCGCAGC

[0088] While the invention has been described through specific embodiments, routine modifications will be apparent to those skilled in the art and such modifications are intended to be within the scope of the present invention.